Lypdiso (omega-3 pentaenoic acid) / Matinas - LARVOL DELTA

ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - P2 | N=100 | Completed | Sponsor: Matinas BioPharma Nanotechnologies, Inc. | Active, not recruiting ➔ Completed

Trial completion • Dyslipidemia • Hypertriglyceridemia

A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study. (PubMed, J Am Heart Assoc) - P2 | "Background MAT9001 is an omega-3 free fatty acid (FFA) formulation containing mainly eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA). EPA+DPA-FFA also reduced triglycerides and high-sensitivity C-reactive protein without increasing low-density lipoprotein cholesterol. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT04177680."

Head-to-Head • Journal • Dyslipidemia • Hypertriglyceridemia • CRP

AMPLIFY: Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL (clinicaltrials.gov) - P3; N=0; Withdrawn; Sponsor: Matinas Biopharma, Inc; N=300 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal • Dyslipidemia • Hypertriglyceridemia

ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - P2; N=100; Active, not recruiting; Sponsor: Matinas BioPharma Nanotechnologies, Inc.; Trial completion date: Mar 2021 ➔ Jun 2021; Trial primary completion date: Dec 2020 ➔ May 2021

Clinical • Trial completion date • Trial primary completion date • Dyslipidemia • Hypertriglyceridemia

Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO Against Vascepa (GlobeNewswire) - P2, N=100; ENHANCE-IT (NCT04177680); Sponsor: Matinas BioPharma; "In the PD population there was a greater reduction in TGs with LYPDISO™ (21.9%) as compared with Vascepa (15.7%); this 39% relative improvement did not achieve statistical significance. In the PP population, there were statistically significant superior reductions in TGs, total cholesterol (TC), VLDL cholesterol (VLDL-C) and high sensitivity C-reactive protein (hsCRP), a well-established inflammatory marker."

P2 data • Dyslipidemia

"$MTNB Matinas BioPharma Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001 https://t.co/yf13YBzqNO" (@stock_titan)

AMPLIFY: Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL (clinicaltrials.gov) - P3; N=300; Not yet recruiting; Sponsor: Matinas Biopharma, Inc

Clinical • New P3 trial • Dyslipidemia • Hypertriglyceridemia

A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules (clinicaltrials.gov) - P1/2; N=48; Completed; Sponsor: Matinas Biopharma, Inc; Recruiting ➔ Completed

Trial completion • Dyslipidemia • Hypertriglyceridemia

ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - P2; N=100; Active, not recruiting; Sponsor: Matinas BioPharma Nanotechnologies, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Dyslipidemia • Hypertriglyceridemia

ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Matinas BioPharma Nanotechnologies, Inc.; Not yet recruiting ➔ Recruiting; Trial completion date: Nov 2020 ➔ Feb 2021

Clinical • Enrollment open • Trial completion date • Dyslipidemia • Hypertriglyceridemia

ENHANCE-IT: Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia (clinicaltrials.gov) - P2; N=100; Not yet recruiting; Sponsor: Matinas BioPharma Nanotechnologies, Inc.

Clinical • New P2 trial

"Acasti's CaPre, Matinas' MAT9001, Astrazeneca's Epanova, Lovaza, Omacor, Omtryg, Vascepa. All purified omega-3 products. Differences in type/mix of omega-3 ( EPA/DHA/DPA) & chemical form. Jury still out on EPA-specific effects. At same dose, all similar? https://t.co/iKCeZN796c" (@BearDownAZ_2019)